# US 11,993,656 B2 · Method of treating IgG4-related disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,993,656 B2
- Document ID: US11993656B2
- Status: Granted
- Kind: B2
- Application number: 17/162,934
- Filed: 2021-01-29
- Published: 2021-08-05
- Granted: 2024-05-28
- Earliest claimed: 2020-01-31
- Applicants: Jason Kihyuk Lee
- Inventors: Jason Kihyuk Lee
- Web page: https://patentgrep.com/patent/US11993656B2

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 38/2026: {IL-4}
- A61P 37/02: Immunomodulators
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This patent relates to a method of treating IgG4-related disease comprising administration of an Interleukin-4 inhibitor/antagonist, an IL-4 receptor alpha inhibitor, or a compound which blocks assembly of IL-4 receptor alpha with IL-13 receptor alpha. The method of treating IgG4-related disease may comprise administration of a JAK inhibitor. The method of treating IgG4-related disease may comprise administration of duplimab and/or pitrakinra.

## Claims

### Claim 1

Method of treating IgG4-Related Disease (RD) selected from the group consisting of IgG4-associated asthma, atopic dermatitis, organ sclerosis (including sclerosing pancreatitis), cholangitis, and organ fibrosis, in a patient in need thereof comprising administering an effective amount of dupilumab or a pharmaceutically acceptable salt thereof, wherein the IgG4-Related Disease is treated or the effects of the disease are diminished by said effective amount.

### Claim 2 (depends on 1)

The method of claim 1 wherein the administration is via a subcutaneous injection.

### Claim 3 (depends on 1)

The method of claim 1 wherein the administration is oral.

### Claim 4 (depends on 1)

The method of claim 1 wherein the administration is a parenteral administration.

### Claim 5 (depends on 1)

The method of claim 1 wherein the effective amount is an initial dose of 600 mg followed by a 300 mg dose every other week, or an initial dose of 400 mg followed by a 200 mg dose every other week.